Suchergebnisse - "Fiore, F"

PubPharm (253)

1

Skeletal muscle overexpression of sAnk1.5 in transgenic mice does not predispose to type 2 diabetes

enthalten in: Scientific reports | 2023

von Pierantozzi, E. | Raucci, L. | Buonocore, S. | +10

2

Impact of Covid-19 pandemic on neuro-oncology multidisciplinary tumor board in the pre-vaccine era : the Normandy experience

enthalten in: Neuro-Chirurgie | 2023

von Lacaud, M. | Leclerc, A. | Marguet, F. | +8

3

Impact of EGFRA289T/V mutation on relapse pattern in glioblastoma

enthalten in: ESMO open | 2023

von Noeuveglise, A. | Sarafan-Vasseur, N. | Beaussire, L. | +10

4

Usefulness of circulating tumor DNA from cerebrospinal fluid in recurrent high-grade glioma

enthalten in: Revue neurologique | 2022

von Fontanilles, M. | Deniel, A. | Marguet, F. | +10

5

Anti-HVEM mAb therapy improves antitumoral immunity bothin vitroandin vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors

enthalten in: bioRxiv.org | 2022

von Demerle, C. | Gorvel, L. | Mello, M. | +12

6

Suppression of black-hole growth by strong outflows at redshifts 5.8-6.6

enthalten in: Nature | 2022

von Bischetti, M. | Feruglio, C. | D'Odorico, V. | +23

7

Strategy for the practice of digestive and oncologic surgery in COVID-19 epidemic situation

enthalten in: Journal de chirurgie viscerale | 2020

von Tuech, J. | Gangloff, A. | Di Fiore, F. | +5

CommentIn: J Visc Surg. 2021 Feb;158(1):96-97. - PMID 33268321

8

Strategy for the practice of digestive and oncological surgery during the Covid-19 epidemic

enthalten in: Journal of visceral surgery | 2020

von Tuech, J. | Gangloff, A. | Di Fiore, F. | +5

CommentIn: J Visc Surg. 2020 Jun;157(3 Suppl 1):S65. - PMID 32305341

9

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

enthalten in: The New England journal of medicine | 2020

von Finn, R. | Qin, S. | Ikeda, M. | +119

CommentIn: N Engl J Med. 2020 May 14;382(20):1953-1955. - PMID 32402168

10

Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial

enthalten in: Contemporary clinical trials communications | 2020

von Pfister, C. | Harter, V. | Allory, Y. | +56

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[26]